CMB-OC: Single-dose domestic bivalent HPV16/18 vaccination impact on vaccine efficacy and cervical cancer screening among young adult women in China
This is a randomized, blinded trial to assess the efficacy of a single-dose regimen of a domestic HPV vaccine against HPV-16/18 incident infections that persist six months or longer, in Chinese women aged 18-26 years old.
Grant dates
Saturday, January 1, 2022 to Tuesday, December 31, 2024
Amount
$80,000
Related program
Health Policy and Systems Sciences
Region
China
Grant number
21-420
Year
2021
Principal Investigator
Shangying HU